Teva and Samsung Bioepis Expand U.S. Biosimilar Reach
Tel Aviv, Israel, and Incheon, South Korea, November 3, 2026 Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd....
immunology
Advertisement
HotSpot Therapeutics to Present HST-2011 Autoimmune Data
Boston, Massachusetts, United States, October 28, 2026 HotSpot Therapeutics, Inc. has announced plans to present new preclinical research on...
Monte Rosa Therapeutics Earns $37.5M Milestone as Novartis Starts Second Phase 2 Trial of MRT-6160
BOSTON, Massachusetts, United States — October 28, 2026 Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing molecular glue...
Lupus Research Alliance Awards $450K to Advance Lupus Therapies
NEW YORK, N.Y. — September 23, 2026 Lupus Research Alliance (LRA) announced the recipients of its 2026 Translational Bridge...
Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
Advertisements
Pharming Gains FDA Priority Review for Lower-Dose Joenja
LEIDEN, Netherlands — September 25, 2026 Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has...
Evommune to Present EVO301 Phase 2a Data at EADV 2026
PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...
Genentech Reports Positive Interim Phase 3 Sefaxersen Data
SOUTH SAN FRANCISCO, Calif. — September 22, 2026 Genentech reported positive prespecified interim results from the ongoing Phase 3...
Amgen Reports Positive Phase 3 Dazodalibep Results
Thousand Oaks, California, U.S., September 22, 2026 Amgen has announced positive topline results from the pivotal Phase 3 OASIZ...
Kelun-Biotech to Present Sac-TMT Phase 3 Data at ESMO 2026
Chengdu, China, September 22, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that multiple Phase 3 studies of sacituzumab tirumotecan...
Advertisement
